Role of Factor XII in hemostasis and thrombosis: clinical implications

References

• Murray CJ, Lopez AD. Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet349(9061), 1269–1276 (1997).
   PubMed Web of Science ®Google Scholar
• Rosenberg RD, Aird WC. Vascular-bed – specific hemostasis and hypercoagulable states. N. Engl. J. Med.340(20), 1555–1564 (1999).
   PubMed Web of Science ®Google Scholar
• Furie B, Furie B. Molecular and cellular biology of blood coagulation. N. Engl. J. Med.326, 800–806 (1992).
   PubMed Web of Science ®Google Scholar
• Ruggeri ZM. Platelets in atherothrombosis. Nat. Med.8(11), 1227–1234 (2002).
   PubMed Web of Science ®Google Scholar
• Furie B, Furie BC. Thrombus formation in vivo. J. Clin. Invest.115(12), 3355–3362 (2005).
   PubMed Web of Science ®Google Scholar
• Walsh PN. Platelet coagulation–protein interactions. Semin. Thromb. Hemost.30(4), 461–471 (2004).
   PubMed Web of Science ®Google Scholar
• Johne J, Blume C, Benz PM et al. Platelets promote coagulation factor XII-mediated proteolytic cascade systems in plasma. Biol. Chem.387(2), 173–178 (2006).
   PubMed Web of Science ®Google Scholar
• Colman RW, Clowes AW, George J, Goldhaber SZ. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. Lippincott Williams & Wilkins, PA, USA (2006).
   Google Scholar
• Levine MN, Raskob G, Landefeld S, Kearon C. Hemorrhagic complications of anticoagulant treatment. Chest119(1 Suppl.), 108S–121S (2001).
   PubMed Web of Science ®Google Scholar
• Weitz JI, Bates SM. New anticoagulants. J. Thromb. Haemost.3(8), 1843–1853 (2005).
   PubMed Web of Science ®Google Scholar
• Schulman S, Ogren M. New concepts in optimal management of anticoagulant therapy for extended treatment of venous thromboembolism. Thromb. Haemost.96(3), 258–266 (2006).
   PubMed Web of Science ®Google Scholar
• Colman RW. Are hemostasis and thrombosis two sides of the same coin? J. Exp. Med.203(3), 493–495 (2006).
   PubMed Web of Science ®Google Scholar
• Kleinschnitz C, Stoll G, Bendszus M et al. Targeting coagulation factor XII provides protection from pathological thrombosis in cerebral ischemia without interfering with hemostasis. J. Exp. Med.203(3), 513–518 (2006).
   PubMed Web of Science ®Google Scholar
• Macfarlane RG. An enzyme cascade in the blood clotting mechanism, and its function as a biochemical amplifier. Nature202, 498–499 (1964).
   PubMed Web of Science ®Google Scholar
• Davie EW, Ratnoff OD. Waterfall sequence for intrinsic blood clotting. Science145, 1310–1312 (1964).
   PubMed Web of Science ®Google Scholar
• Furie B, Furie B. The molecular basis of blood coagulation. Cell53, 505–518 (1988).
   PubMed Web of Science ®Google Scholar
• Lane DA, Philippou H, Huntington JA, Directing thrombin. Blood106, 2605–2612 (2005).
   PubMed Web of Science ®Google Scholar
• Heemskerk JW, Vuist WM, Feijge MA, Reutelingsperger CP, Lindhout T. Collagen but not fibrinogen surfaces induce bleb formation, exposure of phosphatidylserine, and procoagulant activity of adherent platelets: evidence for regulation by protein tyrosine kinase-dependent Ca2+ responses. Blood90(7), 2615–2625 (1997).
   PubMed Web of Science ®Google Scholar
• Rosen ED, Chan JC, Idusogie E et al. Mice lacking factor VII develop normally but suffer fatal perinatal bleeding. Nature390(6657), 290–294 (1997).
   PubMed Web of Science ®Google Scholar
• Bugge TH, Xiao Q, Kombrinck KW et al. Fatal embryonic bleeding events in mice lacking tissue factor, the cell-associated initiator of blood coagulation. Proc. Natl Acad. Sci. USA.93(13), 6258–6263 (1996).
   PubMed Web of Science ®Google Scholar
• Mackman N. Role of tissue factor in hemostasis, thrombosis, and vascular development. Arterioscler. Thromb. Vasc. Biol.24(6), 1015–1022 (2004).
   PubMed Web of Science ®Google Scholar
• Morrissey JH. Tissue factor: a key molecule in hemostatic and nonhemostatic systems. Int. J. Hematol.79(2), 103–108 (2004).
   PubMed Web of Science ®Google Scholar
• Falati S, Liu Q, Gross P et al. Accumulation of tissue factor into developing thrombi in vivo is dependent upon microparticle P-selectin glycoprotein ligand 1 and platelet P-selectin. J. Exp. Med.197(11), 1585–1598 (2003).
   PubMed Web of Science ®Google Scholar
• Chou J, Mackman N, Merrill-Skoloff G et al. Hematopoietic cell-derived microparticle tissue factor contributes to fibrin formation during thrombus propagation. Blood104(10), 3190–3197 (2004).
   PubMed Web of Science ®Google Scholar
• Day SM, Reeve JL, Pedersen B et al. Macrovascular thrombosis is driven by tissue factor derived primarily from the blood vessel wall. Blood105(1), 192–198 (2005).
   PubMed Web of Science ®Google Scholar
• Butenas S, Mann KG. Active tissue factor in blood? Nat. Med.10(11), 1155–1156 (2004).
   PubMedGoogle Scholar
• Colman RW. Contact Activation Pathway: Inflammatory, Fibrinolytic, Anticoagulant, Antiadhesive and Antiangiogenic Activities. Colman RW, Mader VJ, Clowes AW, George J (Eds). Lippincott Williams & Wilkins, PA, USA (2001).
   Google Scholar
• Renne T, Dedio J, David G, Muller-Esterl W. High molecular weight kininogen utilizes heparan sulfate proteoglycans for accumulation on endothelial cells. J. Biol. Chem.275(43), 33688–33696 (2000).
   PubMed Web of Science ®Google Scholar
• Renne T, Schuh K, Muller-Esterl W. Local bradykinin formation is controlled by glycosaminoglycans. J. Immunol.175(5), 3377–3385 (2005).
   PubMed Web of Science ®Google Scholar
• Jaspard E, Wei L, Alhenc-Gelas F. Differences in the properties and enzymatic specificities of the two active sites of angiotensin I-converting enzyme (kininase II). Studies with bradykinin and other natural peptides. J. Biol. Chem.268(13), 9496–9503 (1993).
   PubMed Web of Science ®Google Scholar
• Schmaier AH. The kallikrein–kinin and the renin–angiotensin systems have a multilayered interaction. Am. J. Physiol.285(1), R1–R13 (2003).
   PubMed Web of Science ®Google Scholar
• Nussberger J, Cugno M, Cicardi M. Bradykinin-mediated angioedema. N. Engl. J. Med.347(8), 621–622 (2002).
   PubMed Web of Science ®Google Scholar
• Bork K, Barnstedt SE, Koch P, Traupe H. Hereditary angioedema with normal C1-inhibitor activity in women. Lancet356(9225), 213–217 (2000).
   PubMed Web of Science ®Google Scholar
• Cichon S, Martin L, Hennies HC et al. Increased activity of coagulation factor XII (Hageman factor) causes hereditary angioedema type III. Am. J. Hum. Genet.79(6), 1098–1104 (2006).
   PubMed Web of Science ®Google Scholar
• Dewald G, Bork K. Missense mutations in the coagulation factor XII (Hageman factor) gene in hereditary angioedema with normal C1 inhibitor. Biochem. Biophys. Res. Commun.343(4), 1286–1289 (2006).
   PubMed Web of Science ®Google Scholar
• Levi M, Hack C, de Boer J et al. Reduction of contact activation related fibrinolytic activity in factor XII deficient patients. J. Clin. Invest.88, 1155–1160 (1991).
   PubMed Web of Science ®Google Scholar
• Ghebrehiwet B, Silverberg M, Kaplan AP. Activation of the classical pathway of complement by Hageman factor fragment. J. Exp. Med.153(3), 665–676 (1981).
   PubMed Web of Science ®Google Scholar
• Gailani D, Renne T. The intrinsic pathway of coagulation: a target for treating thromboembolic disease? J. Thromb. Haemost.5, 1106–1112 (2007).
   PubMed Web of Science ®Google Scholar
• Jesty J, Beltrami E. Positive feedbacks of coagulation: their role in threshold regulation. Arterioscler. Thromb. Vasc. Biol.25(12), 2463–2469 (2005).
   PubMed Web of Science ®Google Scholar
• Spronk HM, Govers-Riemslag JW, ten Cate H. The blood coagulation system as a molecular machine. Bioessays25(12), 1220–1228 (2003).
   PubMed Web of Science ®Google Scholar
• Cochrane CG, Revak SD, Wuepper KD. Activation of Hageman factor in solid and fluid phases. A critical role of kallikrein. J. Exp. Med.138(6), 1564–1583 (1973).
   PubMed Web of Science ®Google Scholar
• Cochrane CG, Griffin JH. The biochemistry and pathophysiology of the contact system of plasma. Adv. Immunol.33, 241–306 (1982).
   PubMed Web of Science ®Google Scholar
• Hojima Y, Cochrane CG, Wiggins RC, Austen KF, Stevens RL. In vitro activation of the contact (Hageman factor) system of plasma by heparin and chondroitin sulfate E. Blood63(6), 1453–1459 (1984).
   PubMed Web of Science ®Google Scholar
• Docampo R, de Souza W, Miranda K, Rohloff P, Moreno SN. Acidocalcisomes – conserved from bacteria to man. Nat. Rev. Microbiol.3(3), 251–261 (2005).
   PubMed Web of Science ®Google Scholar
• Smith SA, Mutch NJ, Baskar D et al. Polyphosphate modulates blood coagulation and fibrinolysis. Proc. Natl Acad. Sci. USA.103(4), 903–908 (2006).
   PubMed Web of Science ®Google Scholar
• Kannemeier C, Shibamiya A, Nakazawa F et al. Extracellular RNA constitutes a natural procoagulant cofactor in blood coagulation. Proc. Natl Acad. Sci. USA104, 6388–6393 (2007)
   PubMed Web of Science ®Google Scholar
• Herwald H, Morgelin M, Olsen A et al. Activation of the contact-phase system on bacterial surfaces – a clue to serious complications in infectious diseases. Nat. Med.4(3), 298–302 (1998).
   PubMed Web of Science ®Google Scholar
• Colman RW, Schmaier AH. Contact system: a vascular biology modulator with anticoagulant, profibrinolytic, antiadhesive, and proinflammatory attributes. Blood90(10), 3819–3843 (1997).
   PubMed Web of Science ®Google Scholar
• Pixley RA, Stumpo LG, Birkmeyer K, Silver L, Colman RW. A monoclonal antibody recognizing an icosapeptide sequence in the heavy chain of human factor XII inhibits surface-catalyzed activation. J. Biol. Chem.262(21), 10140–10145 (1987).
   PubMed Web of Science ®Google Scholar
• Clarke BJ, Cote HC, Cool DE et al. Mapping of a putative surface-binding site of human coagulation factor XII. J. Biol. Chem.264(19), 11497–11502 (1989).
   PubMed Web of Science ®Google Scholar
• Citarella F, Ravon DM, Pascucci B et al. Structure/function analysis of human factor XII using recombinant deletion mutants. Evidence for an additional region involved in the binding to negatively charged surfaces. Eur. J. Biochem.238(1), 240–249 (1996).
   PubMedGoogle Scholar
• Ravon DM, Citarella F, Lubbers YT, Pascucci B, Hack CE. Monoclonal antibody F1 binds to the kringle domain of factor XII and induces enhanced susceptibility for cleavage by kallikrein. Blood86(11), 4134–4143 (1995).
   PubMed Web of Science ®Google Scholar
• Ratnoff OD, Colopy JE. A familial hemorrhagic trait associated with a deficiency of a clot-promoting fraction of plasma. J. Clin. Invest.34(4), 602–613 (1955).
   PubMed Web of Science ®Google Scholar
• Ratnoff OD. The George M. Kober lecture. The legacy of John Hageman: new dividends. Trans. Assoc. Am. Physicians98, CLI–CLXI (1985).
   PubMedGoogle Scholar
• Mannhalter C, Fisher M, Hopmeier P, Deutch E. Factor XII activity and antigen concentrations in patients suffering from recurrent thrombosis. Fibrinolysis1, 259 (1987b).
   Google Scholar
• Kuhli C, Scharrer I, Koch F, Ohrloff C, Hattenbach LO. Factor XII deficiency: a thrombophilic risk factor for retinal vein occlusion. Am. J. Ophthalmol.137(3), 459–464 (2004).
   PubMed Web of Science ®Google Scholar
• Halbmayer WM, Mannhalter C, Feichtinger C, Rubi K, Fischer M. The prevalence of factor XII deficiency in 103 orally anticoagulated outpatients suffering from recurrent venous and/or arterial thromboembolism. Thromb. Haemost.68(3), 285–290 (1992).
   PubMed Web of Science ®Google Scholar
• Korte W, Otremba H, Lutz S et al. Childhood stroke at three years of age with transient protein C deficiency, familial antiphospholipid antibodies and F. XII deficiency – a family study. Neuropediatrics25(6), 290–294 (1994).
   PubMed Web of Science ®Google Scholar
• Girolami A, Randi ML, Gavasso S, Lombardi AM, Spiezia F. The occasional venous thromboses seen in patients with severe (homozygous) FXII deficiency are probably due to associated risk factors: a study of prevalence in 21 patients and review of the literature. J. Thromb. Thrombolysis17(2), 139–143 (2004).
   PubMed Web of Science ®Google Scholar
• Zeerleder S, Schloesser M, Redondo M et al. Reevaluation of the incidence of thromboembolic complications in congenital factor XII deficiency – a study on 73 subjects from 14 Swiss families. Thromb. Haemost.82(4), 1240–1246 (1999).
   PubMed Web of Science ®Google Scholar
• Koster T, Rosendaal FR, Briet E, Vandenbroucke JP. John Hageman’s factor and deep-vein thrombosis: Leiden thrombophilia study. Br. J. Haematol.87(2), 422–424 (1994).
   PubMed Web of Science ®Google Scholar
• Saito H. Contact factors in health and disease. Semin. Thromb. Hemost.13(1), 36–49 (1987).
   PubMed Web of Science ®Google Scholar
• Lammle B, Wuillemin W, Huber I et al. Thrombo-embolism and bleeding tendency in congenital factor XII deficiency: a study of 74 subjects from 14 Swiss families. Thromb. Haemost.65, 117–121 (1991).
   PubMed Web of Science ®Google Scholar
• Mann KG, Butenas S, Brummel K. The dynamics of thrombin formation. Arterioscler. Thromb. Vasc. Biol.23(1), 17–25 (2003).
   PubMed Web of Science ®Google Scholar
• Endler G, Marsik C, Jilma B et al. Evidence of a U-shaped association between FXII activity and overall survival. J. Thromb. Haemost. DOI:10.1111/j.1538-7836.2007.02530.x (2007) (Epub ahead of print).
   Google Scholar
• Doggen CJ, Rosendaal FR, Meijers JC. Levels of intrinsic coagulation factors and the risk of myocardial infarction among men: opposite and synergistic effects of factors XI and XII. Blood108(13), 4045–4051 (2006).
   PubMed Web of Science ®Google Scholar
• von dem Borne P, Meijers J, Bouma BN. Feedback activation of factor XI by thrombin in plasma results in additional formation of thrombin that protects fibrin clots from fibrinolysis. Blood86, 3035–3042 (1995).
   PubMed Web of Science ®Google Scholar
• Bouma BN, Mosnier LO. Thrombin activatable fibrinolysis inhibitor (TAFI) – how does thrombin regulate fibrinolysis? Ann. Med.38(6), 378–388 (2006).
   PubMed Web of Science ®Google Scholar
• Meijers J, Tekelenburg W, Bouma B, Bertina R, Rosendaal F. High levels of coagulation factor XI as a risk factor for venous thrombosis. N. Engl. J. Med.342, 696–701 (2000).
   PubMed Web of Science ®Google Scholar
• La Follette L, Gordon EM, Mazur CA, Ratnoff OD, Yamashita TS. Hyperprolactinemia and reduction in plasma titers of Hageman factor, prekallikrein, and high molecular weight kininogen in patients with acute myocardial infarction. J. Lab. Clin. Med.110(3), 318–321 (1987).
   PubMed Web of Science ®Google Scholar
• Hoffmeister HM, Jur M, Wendel HP, Heller W, Seipel L. Alterations of coagulation and fibrinolytic and kallikrein–kinin systems in the acute and postacute phases in patients with unstable angina pectoris. Circulation91(10), 2520–2527 (1995).
   PubMed Web of Science ®Google Scholar
• Citarella F, Felici A, Brouwer M et al. Interleukin-6 downregulates factor XII production by human hepatoma cell line (HepG2). Blood90(4), 1501–1507 (1997).
   PubMedGoogle Scholar
• Gordon EM, Donaldson VH, Saito H, Su E, Ratnoff OD. Reduced titers of Hageman factor (factor XII) in Orientals. Ann. Intern. Med.95(6), 697–700 (1981).
   PubMed Web of Science ®Google Scholar
• Kanaji T, Okamura T, Osaki K et al. A common genetic polymorphism (46 C to T substitution) in the 5'-untranslated region of the coagulation factor XII gene is associated with low translation efficiency and decrease in plasma factor XII level. Blood91(6), 2010–2014 (1998).
   PubMed Web of Science ®Google Scholar
• Kaplan AP. Intrinsic coagulation, thrombosis, and bleeding. Blood87(5), 2090 (1996).
   PubMedGoogle Scholar
• Cooper JA, Miller GJ, Bauer KA et al. Comparison of novel hemostatic factors and conventional risk factors for prediction of coronary heart disease. Circulation102(23), 2816–2822 (2000).
   PubMed Web of Science ®Google Scholar
• Zito F, Drummond F, Bujac SR et al. Epidemiological and genetic associations of activated factor XII concentration with factor VII activity, fibrinopeptide A concentration, and risk of coronary heart disease in men. Circulation102(17), 2058–2062 (2000).
   PubMed Web of Science ®Google Scholar
• Colhoun HM, Zito F, Norman Chan N et al. Activated factor XII levels and factor XII 46C>T genotype in relation to coronary artery calcification in patients with type 1 diabetes and healthy subjects. Atherosclerosis163(2), 363–369 (2002).
   PubMed Web of Science ®Google Scholar
• Grundt H, Nilsen DW, Hetland O, Valente E, Fagertun HE. Activated factor 12 (FXIIa) predicts recurrent coronary events after an acute myocardial infarction. Am. Heart J.147(2), 260–266 (2004).
   PubMed Web of Science ®Google Scholar
• Ton-That TT, Doron D, Pollard BS, Bacher J, Pollard HB. In vivo bypass of hemophilia A coagulation defect by factor XIIa implant. Nat. Biotechnol.18(3), 289–295 (2000).
   PubMed Web of Science ®Google Scholar
• Ponitz V, Pritchard D, Grundt H, Nilsen DW. Specific types of activated Factor XII increase following thrombolytic therapy with tenecteplase. J. Thromb. Thrombolysis22(3), 199–203 (2006).
   PubMed Web of Science ®Google Scholar
• Ponitz V, Pritchard D, Grundt H, Mehus MB, Nilsen DW. Changes of plasma activated Factor XII type A (XIIaA) concentrations following percutaneous coronary intervention (PCI). J. Thromb. Thrombolysis DOI:10.1007/s11239-007-0041-9 (2007) (Epub ahead of print).
   PubMedGoogle Scholar
• Pauer HU, Renne T, Hemmerlein B et al. Targeted deletion of murine coagulation factor XII gene-a model for contact phase activation in vivo. Thromb. Haemost.92(3), 503–508 (2004).
   PubMed Web of Science ®Google Scholar
• Mann KG. Thrombin formation. Chest124(3 Suppl.), 4S–10S (2003).
   PubMed Web of Science ®Google Scholar
• Osterud B, Rapaport SI. Activation of factor IX by the reaction product of tissue factor and factor VII: additional pathway for initiating blood coagulation. Proc. Natl Acad. Sci. USA74(12), 5260–5264 (1977).
   PubMed Web of Science ®Google Scholar
• Gailani D, Broze GJ Jr. Factor XI activation in a revised model of blood coagulation. Science253(5022), 909–912 (1991).
   PubMed Web of Science ®Google Scholar
• Renne T, Pozgajova M, Gruner S et al. Defective thrombus formation in mice lacking coagulation factor XII. J. Exp. Med.202(2), 271–281 (2005).
   PubMed Web of Science ®Google Scholar
• Rosen ED, Gailani D, Castellino FJ. FXI is essential for thrombus formation following FeCl3-induced injury of the carotid artery in the mouse. Thromb. Haemost.87(4), 774–776 (2002).
   PubMed Web of Science ®Google Scholar
• Wang X, Cheng Q, Xu L et al. Effects of factor IX or factor XI deficiency on ferric chloride-induced carotid artery occlusion in mice. J. Thromb. Haemost.3(4), 695–702 (2005).
   PubMed Web of Science ®Google Scholar
• Wang X, Smith PL, Hsu MY et al. Effects of factor XI deficiency on ferric chloride-induced vena cava thrombosis in mice. J. Thromb. Haemost.4(9), 1982–1988 (2006).
   PubMed Web of Science ®Google Scholar
• Tans G, Janssen-Claessen T, Rosing J, Griffin JH. Studies on the effect of serine protease inhibitors on activated contact factors. Application in amidolytic assays for factor XIIa, plasma kallikrein and factor XIa. Eur. J. Biochem.164(3), 637–642 (1987).
   PubMedGoogle Scholar